Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

PHASE2CompletedINTERVENTIONAL
Enrollment

251

Participants

Timeline

Start Date

December 28, 2018

Primary Completion Date

May 19, 2020

Study Completion Date

May 19, 2020

Conditions
Atopic Dermatitis
Interventions
DRUG

Delgocitinib cream

Cream for topical application

DRUG

Delgocitinib cream vehicle

The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.

Trial Locations (31)

2010

Leo Pharma Investigational Site, Darlinghurst

2217

Leo Pharma Investigational Site 1, Kogarah

Leo Pharma Investigational Site, Kogarah

3002

Leo Pharma Investigational Site, East Melbourne

3053

Leo Pharma Investigational Site, Carlton

4102

Leo Pharma Investigational Site, Woolloongabba

5073

Leo Pharma Investigational Site, Hectorville

10019

Leo Pharma Investigational Site, New York

19104

Leo Pharma Investigational Site, Philadelphia

27262

Leo Pharma Investigational Site, High Point

35209

Leo Pharma Investigational Site, Birmingham

48202

Leo Pharma Investigational Site, Detroit

60611

Leo Pharma Investigational Site, Chicago

90033

Leo Pharma Investigational Site, Los Angeles

90045

Leo Pharma Investigational Site, Los Angeles

91436

Leo Pharma Investigational Site, Encino

92701

Leo Pharma Investigational Site, Santa Ana

90274-7604

Leo Pharma Investigational Site, Rolling Hills Estates

T3A 2N1

Leo Pharma Investigational Site, Calgary

T5K 1X3

Leo Pharma Investigational Site, Edmonton

V3R 6A7

Leo Pharma Investigational Site, Surrey

R3M 3Z4

Leo Pharma Investigational Site, Winnipeg

E3B 1G9

Leo Pharma Investigational Site, Fredericton

L5H 1G9

Leo Pharma Investigational Site, Mississauga

L4M 7G1

Leo Pharma Investigational Site, Barrie

L3P 1X2

Leo Pharma Investigational Site, Markham

K9J 5K2

Leo Pharma Investigational Site, Peterborough

L4C 9M7

Leo Pharma Investigational Site, Richmond Hill

M2M 4J5

Leo Pharma Investigational Site, Toronto

M2W 2N2

Leo Pharma Investigational Site, Toronto

M3H 5Y8

Leo Pharma Investigational Site, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

LEO Pharma

INDUSTRY

NCT03725722 - Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis. | Biotech Hunter | Biotech Hunter